These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16720679)

  • 1. A step in the right direction.
    Swain SM
    J Clin Oncol; 2006 Aug; 24(23):3717-8. PubMed ID: 16720679
    [No Abstract]   [Full Text] [Related]  

  • 2. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
    Paik S; Tang G; Shak S; Kim C; Baker J; Kim W; Cronin M; Baehner FL; Watson D; Bryant J; Costantino JP; Geyer CE; Wickerham DL; Wolmark N
    J Clin Oncol; 2006 Aug; 24(23):3726-34. PubMed ID: 16720680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple gene signatures aim to qualify risk in breast cancer.
    Tuma RS
    J Natl Cancer Inst; 2005 Mar; 97(5):332. PubMed ID: 15741566
    [No Abstract]   [Full Text] [Related]  

  • 4. Trial and error: prognostic gene signature study design altered.
    Tuma RS
    J Natl Cancer Inst; 2005 Mar; 97(5):331-3. PubMed ID: 15741565
    [No Abstract]   [Full Text] [Related]  

  • 5. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
    De Maeyer L; Van Limbergen E; De Nys K; Moerman P; Pochet N; Hendrickx W; Wildiers H; Paridaens R; Smeets A; Christiaens MR; Vergote I; Leunen K; Amant F; Neven P
    J Clin Oncol; 2008 Jan; 26(2):335-6; author reply 336-8. PubMed ID: 18182677
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem.
    Schott A; Hayes DF
    J Clin Oncol; 2004 Dec; 22(23):4660-2. PubMed ID: 15505274
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic markers of local relapse in rectal cancer: are we any further forward?
    Johnston PG
    J Clin Oncol; 2006 Sep; 24(25):4049-50. PubMed ID: 16943520
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions.
    Markopoulos C; Xepapadakis G; Venizelos V; Tsiftsoglou A; Misitzis J; Panoussis D; Antonopoulou Z; Stathoulopoulou M; Zobolas V; Gogas H
    Eur J Surg Oncol; 2012 May; 38(5):413-9. PubMed ID: 22425282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A big trial for a new technology: TransBIG Project takes microarrays into clinical trials.
    Tuma RS
    J Natl Cancer Inst; 2004 May; 96(9):648-9. PubMed ID: 15126595
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Kunkler I
    J Natl Cancer Inst; 2005 Aug; 97(15):1162-3; author reply 1163-4. PubMed ID: 16077078
    [No Abstract]   [Full Text] [Related]  

  • 11. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.
    Mehta RS
    J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer].
    Zhang P; Xu BH; Ma F; Li Q
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):128-31. PubMed ID: 20403244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-generation genomic tests for breast cancer treatment.
    Andre F; Delaloge S
    Lancet Oncol; 2010 Jan; 11(1):6-7. PubMed ID: 20005177
    [No Abstract]   [Full Text] [Related]  

  • 15. More evidence that locoregional radiation therapy improves survival: what should we do?
    Whelan T; Levine M
    J Natl Cancer Inst; 2005 Jan; 97(2):82-4. PubMed ID: 15657332
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 18. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
    J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancer: a short review.
    Elias AD
    Am J Clin Oncol; 2010 Dec; 33(6):637-45. PubMed ID: 20023571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.